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Abstract
BACKGROUND: Thyroid hormones are key regulators of essential cellular processes, including proliferation, 
differentiation, and finally, apoptosis.
AIM: The aim of the study was to detect changes in the expression of apoptosis and cell cycle pathway-focused 
genes in patients with different forms of thyroid pathology.
PATIENTS AND METHODS: Thirty-six patients with thyroid pathology were enrolled in the study. We used the 
pathway-specific real-time PCR array (Neurotrophins and Receptors RT2 Profiler PCR Array, QIAGEN, Germany) 
to identify and verify apoptosis and cell cycle pathway-focused genes expression in patients with post-operative 
hypothyroidism, hypothyroidism as a result of autoimmune thyroiditis (AIT) and AIT with elevated serum and anti-
thyroglobulin (anti-TG) and anti-thyroid peroxidase (anti-TPO) antibodies.
RESULTS: It was shown that patients with elevated serum anti-TG and anti-TPO antibodies and with hypothyroidism 
resulting from AIT had a significantly lower expression of FAS, TGFB, TP53, and TGFA, while the expression of 
CD40 was increased. The mRNA levels of BCL2 and BAX decreased in the patients with elevated serum anti-TG 
and anti-TPO antibodies and increased in the patients with hypothyroidism, resulting from AIT and post-operative 
hypothyroidism. The patients with hypothyroidism resulting from AIT and post-operative hypothyroidism had 
significantly lower expression of HSPB1. NF1 expression did not change in all groups of patients. 
CONCLUSION: The results of this study demonstrate that AIT and hypothyroidism affect the mRNA-level expression 
of apoptosis and cell cycle pathway-focused genes in a gene-specific manner and that these changes to gene 
expression can be responsible for the apoptosis signs and symptoms associated with thyroid pathology.
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Introduction
Thyroid disorders affect approximately 6.6% 
of the world population. In the Central, Northern, 
and Eastern Europe, there is a recorded increasing 
incidence of such disorders since the Chernobyl 
nuclear accident in 1986 [1]. The most prevalent 
autoimmune thyroid disorder, Hashimoto’s thyroiditis 
(HT), results in lymphocytic infiltration of the thyroid 
gland, often followed by gradual destruction and 
fibrous replacement of the thyroid parenchymal 
tissue. Antibodies against thyroperoxidase and 
thyroglobulin are of immunoglobulin G class, both 
with high affinity for their respective antigens. Multiple 
susceptibility genes may be involved in the disease 
development, some of which are implicated in other 
autoimmune diseases, while others are specific for 
thyroid autoimmunity [2].
Thyroid hormones (THs) are key regulators 
of essential cellular processes, including proliferation, 
differentiation, and finally, apoptosis [3], involving the 
interaction of many pro- and anti-apoptotic genes. 
A number of cell cycle regulatory proteins modulate 
programmed cell death. The intrinsic apoptosis 
pathway involves DNA damage and/or free radical 
generation; activated nuclear or mitochondrial p53 is 
an important mediator of such signaling. The extrinsic 
apoptosis pathway is activated by cell surface factors, 
for example, tumor necrosis factor-α (TNF-α) and Fas 
ligand [4].
Transcriptome analysis is an important 
indicator of the functional activity of cells [5]. THs 
affect transcription of a number of genes relevant 
to apoptosis [6], but the studies so far have been 
inconclusive. The actions of THs can be classified into 
two main mechanisms: A non-genomic effect initiated 
at the cell membrane mediating downstream gene 
expression through the integrin αvβ3; and transcription 
initiated by interactions with nuclear TH receptor 
proteins followed by binding to TH response elements 
of specific downstream genes [7].
We aimed to detect changes in the expression 
of apoptosis and cell cycle pathway-focused genes in 
patients with different forms of thyroid pathology.
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Materials and Methods
Thirty-six patients with thyroid pathology 
were enrolled in the study. They were divided into 
three groups: Group 1 included 12 patients with 
post-operative hypothyroidism; Group 2 included 12 
patients with hypothyroidism as a result of autoimmune 
thyroiditis (AIT); Group 3 included 12 patients with 
AIT with rising serum and anti-thyroglobulin (anti-TG) 
and anti-thyroid peroxidase (anti-TPO) antibodies. 
Control group included 12 healthy individuals, which 
were recruited randomly, without matching for age or 
sex.
Blood specimens were collected between 8 
and 10 am after an overnight fast. Free triiodothyronine 
(fT3) (normal range 1.2–3.2 nmol/L), free thyroxine 
(fT4) (normal range 6.0–13.0 pmol/L for males and 
7.0-13.5 pmol/L for females), thyroid-stimulating 
hormone (TSH) (normal range 0.3–4.0 mIU/mL), anti-
TPO (normal range 0–30 IU/mL), and anti-TG (normal 
range 0–65 IU/mL) antibodies levels were determined 
using STAT FAX303/Plus (Awareness Technology Inc., 
USA).
Hypothyroidism was diagnosed due to the 
recommendations of the American Association of 
Clinical Endocrinologists 2012 [8]. The diagnosis of AIT 
was performed according to circulating antibodies to 
thyroid antigens (anti-TPO and anti-TG) and reduced 
echogenicity on thyroid sonogram in a patient with 
proper clinical features [8].
Patients under the age of 18 or with any 
malignancy, inflammation associated rheumatic 
diseases or acute/chronic infection, cases with diabetes 
mellitus, cases with cardiovascular or cerebrovascular 
diseases, pregnant women and those with chronic 
hepatic or renal diseases, those who use any drugs that 
could interfere with thyroid function were excluded from 
the study.
Statement of ethics
All patients provided informed written consent 
and protocol of research was ethically approved by 
the HSEEU “Bukovinian State Medical University” 
and Chernivtsi Regional Endocrinology Center ethics 
committees.
We used a pathway-specific PCR array 
(Neurotrophins and Receptors RT2 Profiler PCR 
Array, QIAGEN, Germany) to identify and verify 
genes expression in each individual of the studied 
and control groups. The Human Neurotrophin and 
Receptors RT² Profiler PCR Array is designed for 
expression analysis of 84 genes related to neuronal 
processes plus five housekeeping genes and three 
controls. Neurotrophic signaling molecules on this 
array include NTs and neuropeptides along with their 
receptors. Genes involved in the normal functions 
of the neuronal system include neuronal cell growth 
and differentiation and neuronal regeneration and 
survival. The array also contains the cytokines and 
receptors involved in neuronal signaling along with 
genes involved in the transmission of nerve impulses, 
genes involved in neuronal apoptosis in response 
to neurotrophic factors and transcription factors 
and regulators indicative of the activation pathways 
downstream of the neuronal system. The expression 
of these genes was reliably analyzed using real-time 
PCR.
Experimental procedures
RNA isolation
Total RNA was isolated from white blood 
cells using NucleoZOL (Macherey-Nagel, Germany) 
according to the manufacturer’s instructions. NucleoZOL 
is designed for the isolation of total RNA (small and 
large RNA) in single or separate fractions from a variety 
of sample materials such as cells, tissue, and liquids 
from human or animal origin. White blood cells were 
lysed and homogenized in NucleoZOL reagent based 
on guanidinium thiocyanate and phenol.
cDNA synthesis
The RNA quality was determined using a 
spectrophotometer and was reverse transcribed. 
The concentration and quality of the isolated total 
RNA were determined on a spectrophotometer 
NanoDrop (Thermo Scientific™, USA). For the reverse 
transcription procedure, using a cDNA conversion RT² 
First Strand Kit (QIAGEN, Germany, Cat. no. 330401), 
RNA samples with the ratio А260/А280 within the range 
of 1.8-2.2 were selected.
The RT2 HT First Strand Kit procedure 
comprises two steps: Elimination of genomic DNA 
contamination and reverse transcription, which 
enables fast and easy handling of 96 RNA samples 
simultaneously. After genomic DNA elimination, the 
RNA sample undergoes reverse transcription with 
an RT master mix, as well as random hexamers and 
oligo-dT prime reverse transcription to capture more 
difficult-to-detect genes.
PCR array
The cDNA was then used with RTІ Profiler PCR 
Array (QIAGEN, Cat. no. PAHS-031Z) in combination 
with RTІ SYBR® Green qPCR Mastermix (QIAGEN, 
Cat. no. 330504), following the complete RT2 Profiler 
PCR Array procedure (www.qiagen.com). Samples 
were assigned to control and study groups. CT values 
were normalized based on a/an automatic selection 
from the full panel of reference genes.
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Any Ct value >35 was considered to be 
a negative call. The RT2 Profiler PCR Array data 
analysis software calculates the fold change based 
on the widely used and agreed upon ΔΔ Ct method. 
The data analysis web portal calculates fold change/
regulation using delta-delta CT method, in which delta 
CT is calculated between the gene of interest (GOI) 
and an average of reference genes (HKG), followed by 
delta-delta CT calculations (delta CT [Test Group]-delta 
CT [Control Group]). Fold change is then calculated 
using 2^ (-delta-delta CT) formula. These data analysis 
report was exported from the QIAGEN web portal at 
GeneGlobe. The software allows to define the best 
reference genes for normalization. In further analysis, 
apoptosis and cell cycle pathway-focused genes were 
selected for this work; a list of these genes is given in 
Table 1.
Table 1: Apoptosis and cell cycle pathway-focused genes
UniGene RefSeq Symbol Description
Hs.624291 NM_004324 BAX BCL2-associated X protein
Hs.150749 NM_000633 BCL2 B-cell CLL/lymphoma 2
Hs.472860 NM_001250 CD40 CD40 molecule, TNF receptor superfamily 
member 5
Hs.667309 NM_000043 FAS Fas (TNF receptor superfamily, member 6)
Hs.520973 NM_001540 HSPB1 Heat shock 27kDa protein 1
Hs.113577 NM_000267 NF1 Neurofibromin 1
Hs.170009 NM_003236 TGFA Transforming growth factor, alpha
Hs.645227 NM_000660 TGFB1 Transforming growth factor, beta 1
Hs.437460 NM_000546 TP53 Tumor protein p53
Statistical analysis of PCR array data
The RT2 Profiler PCR Array Data Analysis 
software does not perform any statistical analysis 
beyond the calculation of p-values using a Student’s 
t-test (two-tail distribution and equal variances between 
the two samples) based on the triplicate 2^(-ΔCT) 
values for each gene in the experimental group 
compared to the control group. The microarray quality 
control published results indicating that a ranked list 
of genes based on a fold-change and such a p-value 
calculation was sufficient to demonstrate reproducible 
results across multiple microarrays and PCR arrays, 
including the RT2 Profiler PCR arrays.
Results
Gene regulators of apoptosis are divided into 
anti-apoptotic (BCL2, HSPB1, TGFA); pro-apoptotic 
(BAX, FAS, NF1, TP 53) and promiscuous (CD40, 
TGFB1) (Figure 1a-c). The results from RT2 Profiler 
Apoptosis and cell cycle pathway-focused genes 
expression analysis indicated that in Group 1 which 
include patients with post-operative hypothyroidism 
among anti-apoptotic genes, the expression 
of BCL2 and TGFA was increased by 3.2 and 
4.5 times correspondingly, whereas the HSPB1 was 
downregulated (11.8-fold) (Table 2 and Figure 2). The 
expression of pro-apoptotic genes, such as BAX, FAS, 
NF1, and TP 53, significantly did not change (Figure 1a). 
While the expression of promiscuous genes, regulators 
of apoptosis have changed in different ways. Thus, a 
decrease in CD40 expression (3.9-fold) was noted, while 
TGFB1 expression was increased (4.9-fold) (Figure 1a).
In patients with hypothyroidism as a result of 
AIT (Group 2), the expression of apoptosis regulator 
genes changed as follows: Among anti-apoptotic 
genes, BCL2 was upregulated (6,6-fold), on the other 
hand, TGFA and HSPB1 were downregulated by 46.4 
and 11.2 times correspondingly (Table 2). Among pro-
apoptotic genes, the increase in the expressions of BAX 
(11.6-fold) was observed; in contrast, the expressions 
of FAS (28.8-fold) and TP53 (66.9-fold) was decreased 
(Figure 1b). As shown in Table 2, the expression of 
Figure 1:  (a-c) Differential  expression of mRNA apoptosis and cell 
cycle  pathway-focused  genes  in  patients  with  thyroid  pathology.
 – upregulated genes,  – unchanged genes,  – downregulated 
genes
c
b
a
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CD 40 was significantly higher in Group 2 (6.3-fold), 
whereas the expression of TGFB1 was significantly 
lower in this group (21.8-fold).
Figure 2: Heat map plot of mRNA apoptosis and cell cycle pathway-
focused genes expression in patients with thyroid pathology
We noted that in Group 3 which includes 
patients with AIT with rising serum anti-TG and anti-
TPO autoantibodies that anti-apoptotic genes such 
as BCL2 and TGFA were downregulated by 26.4 and 
17.6 times correspondingly. At the same time, mRNA 
level of HSPB1 was significantly increased (6.0-fold) 
(Figure 1c and Figure 2). Reduction in BAX (23.2-
fold), FAS (44.5-fold), and TP53 (29.7-fold), mRNAs 
were found in Group 3. The expression of CD40 was 
markedly increased in Group 3 (10.0-fold), whereas 
mRNA level of TGFB1 was significantly decreased 
(38.5-fold).
The p values are calculated based on a 
Student’s t-test of the replicate 2^ (-Delta CT) values for 
each gene in the control group and study groups
Discussion
The B cell lymphoma-2 (BCL-2) family of 
proteins is key regulators of programmed cell death. 
They are predominantly localized on the outer 
membrane of mitochondria, regulating a critical 
decision point, cytochrome c release. This protein 
family consists of both anti-apoptotic (Bcl-2, Bcl-XL) 
and pro-apoptotic (Bcl-2 associated protein X, Bax; 
B-cell homologous antagonist/killer, bak) molecules. 
The survival or death of a cell depends on the balance 
of BCL2 levels induced through a dynamic process by 
cellular signaling modulating the expression of pro- 
or anti-apoptotic proteins [9]. In our study, BCL2 was 
significantly suppressed in the group of AIT patients 
with increased serum autoantibodies, such as anti-TG 
and anti-TPO, while in the patients with hypothyroidism 
stemming from AIT and post-operative hypothyroidism, 
BCL2 expression was elevated.
After a cell receives apoptotic signals, 
BAX protein migrates from the cytoplasm to the 
mitochondrial membrane, inducing its damage and 
subsequent apoptosis. In our study, a decrease in BAX 
expression was found in AIT patients with elevated 
serum autoantibodies, such as anti-TG and anti-TPO, 
while in patients with hypothyroidism as a result of AIT 
or post-operative hypothyroidism, BAX expression was 
increased.
Singh et al. evaluated the effect of 
hypothyroidism on Bcl-2 family gene expression in the 
developing rat cerebellum. The anti-apoptotic genes 
Bcl-2 and Bcl-XL were downregulated and the pro-
apoptotic gene BAX was expressed at higher levels 
compared with the euthyroid state. These results suggest 
that normal levels of TH prevent cerebellar apoptosis, 
whereas hypothyroidism not only increases the extent 
but also the duration of apoptosis by downregulating 
the anti-apoptotic genes and maintaining a high level of 
the pro-apoptotic gene BAX [4].
A study by Alva-Sanchez et al. examined 
the expression of specific proteins that control cell 
proliferation (cycline-D1), cell arrest (p21), DNA 
damage (p53), or apoptosis (Bax and Bcl2) in the 
hippocampus of hypothyroid rats treated with the NMDA 
receptor (NMDAR) blocker MK-801 during the induction 
Table 2: Differential expression of mRNA apoptosis and cell cycle pathway-focused genes in patients with different thyroid pathology
Gene symbol Up-down regulation (comparing to the control group)
Patients with post-operative hypothyroidism 
(Group 1)
Patients with hypothyroidism as a result of AIT 
(Group 2)
Patients with AIT with rising serum anti-TG and anti-TPO autoantibodies 
(Group 3)
Fold regulation Fold regulation Fold regulation
BAX 2.8014 (p=0.053441) 11.5792 (p=0.001038) −23.2202 (p=0.000154)
BCL2 3.2106 (p=0.004666) 6.5893 (p=0.033823) −26.3667 (p=0.000804)
CD40 −3.883 (p=0.000337) 6.3209 (p=0.028077) 9.9592 (p=0.044469)
FAS 2.6018 (p=0.057688) −28.7709 (p=0.000465) −44.4459 (p=0.000178)
HSPB1 −11.8255 (p=0.00008) −11.1827 (p=0.000501) 5.9906 (p=0.047287)
NF1 −1.0574 (p=0.64743) −1.1018 (p=0.372849) −1.1308 (p=0.402653)
TGFA 4.4573 (p=0.009709) −46.4155 (p=0.003209) −17.5976 (p=0.004579)
TGFB1 4.8663 (p=0.004832) −21.8042 (p=0.021417) −38.514 (p=0.000167)
TP53 2.0555 (p=0.051796) −66.8661 (p=0.000361) −29.6641 (p=0.000315)
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of hypothyroidism [10]. Hypothyroidism increased the 
expression of markers of DNA damage, cell arrest, 
and apoptosis but did not affect the marker of cell 
proliferation. NMDAR blockade prevented the increase 
in markers of DNA damage and apoptosis but did not 
affect cell arrest or cell proliferation. This suggests 
that hypothyroidism promotes cell death mainly by an 
excitotoxic effect of glutamate.
Several mechanisms are likely to be involved 
in determining the progress of an autoimmune thyroid 
disease toward either hypothyroidism or a clinical 
syndrome known as HT. The regulation of Fas/FasL/
Bcl-2 expression in HT causes thyrocyte apoptosis, 
tissue damage, and a gradual reduction in thyrocyte 
numbers, leading to hypothyroidism. Other authors have 
shown that THs inhibit apoptosis of early differentiating 
cerebellar granule neurons through an increase in the 
levels of Bcl-2 protein. Thus, increased serum Bcl-2 
may be linked to accelerated apoptosis. Elevated 
serum Bcl-2 was reported in euthyroid HT patients in 
contrast to controls and euthyroids [11].
Cluster of differentiation 40 (CD40), a member 
of the TNFR superfamily, is associated with multiple 
autoimmune diseases, including HT. Although the 
CD40 gene is a general autoimmunity gene, it is unique 
among autoimmunity genes because it is expressed and 
functional in many non-immune tissues, where it has 
been shown to contribute to nonspecific inflammatory 
responses [12]. We found that patients with post-
operative hypothyroidism had significantly lower 
expression of CD40 compared with the control group. 
On the other hand, high levels of serum anti-TG and 
anti-TPO antibodies were associated with increased 
expression of CD40. These findings are supported by 
Bilir et al. who also found a significantly higher CD40L 
level in patients with HT compared to healthy controls. 
TSH, anti-TG, and anti-TPO levels were higher in the 
HT group than the healthy control group [13].
Apoptosis features prominently in HT because 
the extrinsic apoptosis induction pathway is activated 
by the means of binding FasL (CD95L) with its receptor 
Fas (CD95). After binding the ligand, Fas combines with 
adaptive protein, which binds procaspase-8. Activated 
caspase-8 induces cysteine proteases or caspase-3 
complex which selectively affects proteins, either 
suppressing their activity or activating them, and leads 
to the destruction of a cell [14]. In our study, FAS was 
downregulated in patients with hypothyroidism resulting 
from AIT and in patients with AIT with rising serum 
autoantibodies. Meanwhile, in a group of patients with 
post-operative hypothyroidism, the expression of FAS 
did not change. These results suggest that a high level 
of serum autoantibodies, such as anti-TG and anti-
TPO, suppress the expression of FAS.
Bossowski et al. reported a significantly higher 
expression of apoptotic molecules Fas/FasL on the 
surface of thyroid cells and elevated expression of 
pro-apoptotic proteins Fas/FasL in thyroid cells [15]. In 
addition, in this study, a significantly lower percentage 
of lymphocytes incoming to the thyroid gland was 
observed, which demonstrated the expression of these 
molecules. As a result, follicular cells of the thyroid are 
destroyed either through the mechanism of apoptosis 
or because of T cells activity, finally causing the 
development of hypothyroidism.
In thyrocytes in the active phase of HT Fas and 
FasL expression were elevated, but these proteins were 
also expressed in normal thyrocytes [16]. Nonetheless, 
their concentration was insufficient to initiate apoptosis. 
Moreover, the authors suggested that the changes in 
the distribution of apoptotic markers in thyrocytes can 
be caused by pro-inflammatory cytokines released by 
macrophages and Th1 lymphocytes such as IFNG, 
TNFA, and IL-12. Among others, they are responsible for 
increased Fas expression on the surface of thyrocytes 
and elevated concentration of procaspases 8, 10, 
and 7; increased expression of Bid, and to a lesser 
extent Bcl-XL and Bak, as well as a slightly decreased 
Bcl-2 levels. This stimulation activates apoptosis in 
the mechanism of suicide or fratricide, leading to the 
destruction of follicular cells of the thyroid. Łacka 
and Maciejewski studied the role of apoptosis in the 
pathogenesis of AIT. They found increased Fas/FasL 
expression, caspases, and Bid protein concentrations 
decreased Bcl-2 concentration, and at the same time, 
increase of Bcl-2 within intrathyroidal lymphocytes [17]. 
This stimulates thyrocyte apoptosis and damage to 
thyroid parenchyma. Apoptotic factor of thyrocytes was 
shown to correlate with clinical symptoms of HT [15]. 
We also know that TSH, thyroid-stimulating antibody, 
and thyroid-stimulating blocking antibody inhibit 
apoptosis by means of decreasing Fas expression [17]. 
In contrast, Bona et al. [18] reported a direct correlation 
between the concentration of anti-TPO antibodies 
in blood serum and the resistance of T cells to Fas-
induced apoptosis in a group of untreated patients.
The HSPB1 gene expresses HSPB1, heat 
shock protein beta-1 protein (also known as Hsp27, 
heat shock protein 27). This protein is a member of the 
heat shock protein family, which helps to protect cells 
under adverse conditions such as infection, inflammation, 
exposure to toxins, elevated temperature, injury, and 
disease [19]. HSPB1 acts as a potent inhibitor of 
apoptosis signaling [20]. Havasi et al. show that HSPB1 
can indirectly inhibit BAX activation/oligomerization 
and MOMP induction to reduce cytochrome c release 
from the mitochondria [21]. HSPB1 mutations were 
associated with progressive degeneration of peripheral 
nerves in Charcot-Marie-Tooth disease type 2F and 
distal hereditary motor neuropathy [22].
In this study, the expression of HSPB1 was 
decreased in patients with hypothyroidism resulting 
from AIT as well as post-operative hypothyroidism. 
In contrast, HSPB1 was significantly upregulated in 
a group of patients with rising serum autoantibodies. 
These results suggest that the high level of serum 
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autoantibodies, such as anti-TG and anti-TPO will 
upregulate the expression of HSPB1.
The neurofibromatosis type I (NF-1) gene 
encodes neurofibromin – a GTPase-activating 
Figure 3: Gene interaction network and functional linkages of apoptosis and cell cycle pathway-focused genes
B - Clinical Sciences Endocrinology
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protein that downregulates the cellular p21-ras 
proto-oncogene [23]. It is expressed in neurons, the 
adrenal medulla, in endothelial and glial cells [24]. 
The neurofibromin protein is thought to play a key role 
in autoimmune diseases and NF-1 [25]. We did not 
detect changes in the transcriptional activity of NF1 
gene in patients with primary hypothyroidism and AIT. 
In the literature, HT is rarely associated with NF-1, 
and only a few cases have been reported so far. For 
instance, Nabi described a 30-year-old woman with 
the concomitant occurrence of goiter and NF-1 [26]. 
Sasazawa et al. reported a 51-year-old patient with 
NF1 and HT who suffered a coma as a cause of 
myxedema [27].
Transforming growth factor α (TGFA) can be 
produced by a variety of cells, primarily of ectodermal 
origin, and may interact with the epidermal growth 
factor (EGF) receptor to induce growth and proliferation 
responses during cell contact. It is expressed in several 
tissues, and throughout the entire lifespan of an 
organism, from embryogenesis to the adult phase. A 
study of the physiological action of triiodothyronine T3 on 
the expression of TGFA mRNA in MCF7 cells by inhibition 
of RNA polymerase II and the MAPK/ERK pathway 
found that T3 increases the expression of TGFA mRNA 
in MCF7 cells within 4 h of treatment [28]. Inhibition of 
RNA polymerase II modulates the effect of T3 treatment 
on the expression of TGFA in MCF7 cells. Activation of 
the MAPK/ERK pathway is not required for T3 to affect 
the expression of TGFA mRNA. We found that in the 
patients with elevated serum autoantibodies anti-TG and 
anti-TPO and the patients with hypothyroidism resulting 
from AIT, the expression of TGFA decreased. In contrast, 
TGFA was upregulated in the group of patients with post-
operative hypothyroidism.
Transforming growth factor β (TGF-β) gene is 
one of the key genes implicated in genetic predisposition 
to autoimmune diseases, particularly HT [29]. T allele 
of +369T/C SNP, resulting in reduced secretion of 
TGF-β, was found to be more frequent in the cases of 
severe hypothyroidism than mild hypothyroidism [30]. 
Treatment of hepatic HepG2 cells stably expressing 
TRs with T3 inhibited their proliferation by arresting 
them at the transition point between G1 and S phases. 
In addition to other changes, a stimulation of TGF-β 
on the transcription level was observed. The activity 
of its promoter was increased as much as 8-fold by 
T3, but this effect was dependent on the presence of 
active TRs. It was also shown that TGF-β neutralizing 
antibodies and not control antibodies could reverse 
anti-proliferative effect of T3 in HepG2 cells, suggesting 
that this is a TGF-β-mediated mechanism [31]. In this 
study, TGFB1 was significantly downregulated in the 
patients with elevated serum autoantibodies anti-TG 
and anti-TPO, while in the patients with hypothyroidism 
resulting from AIT the expression of TGFA decreased. 
In contrast, TGFB1 was upregulated in patients with 
post-operative hypothyroidism.
The tumor suppressor p53 (TP53) is a 
short-lived phosphoprotein present in low amounts 
in the nuclei of normal cells. Activated nuclear 
or mitochondrial p53 is an important mediator of 
mitochondrial death signaling. TH may influence the 
function of p53 by altering its expression, as shown in 
T47D human breast ductal carcinoma cell line, where 
p53 levels increased in a T3 concentration-dependent 
manner [32], or by affecting its post-transcriptional 
modification, as shown in T4-treated HEK293 and in 
HeLa cells that do not express TRs. Such treatment 
promoted p53 phosphorylation by mitogen-activated 
protein kinase [33]. In this study, reduction in TP53 
mRNA was found in the patients with elevated serum 
autoantibodies anti-TG and anti-TPO, and with 
hypothyroidism resulting from AIT, while in the patients 
with post-operative hypothyroidism the expression of 
TP53 increased.
Therefore, we found that the patients with 
elevated serum autoantibodies anti-TG and anti-TPO 
and with hypothyroidism resulting from AIT had a 
significantly lower expression of FAS, TGFB, TP53, and 
TGFA, while the expression of CD40 increased. The 
mRNA levels of BCL2 and BAX decreased in the patients 
with elevated serum autoantibodies anti-TG and anti-
TPO and increased in the patients with hypothyroidism 
resulting from AIT and post-operative hypothyroidism. 
The patients with hypothyroidism resulting from AIT and 
post-operative hypothyroidism had significantly lower 
expression of HSPB1. NF1 expression did not change 
in all groups of patients.
Using our data on apoptosis and cell cycle 
pathway-focused genes, we have built gene networks 
using the GeneMANIA software (http://genemania.org). 
This allowed us to determine how the candidate genes 
interact with other genes and generate hypotheses 
about gene function, analyze gene lists, and prioritize 
genes for functional assays. As presented in Figure 3, 
within the gene network that controls the interaction 
and functional linkages of apoptosis, cell cycle, and cell 
differentiation regulators, the closest functional linkages 
were observed between the genes HSPB1 and HSPB6, 
BCL2 and BCL2L11, TP53 and HMGB1, and FAS and 
FADD.
Conclusions
The results of this study demonstrate that AIT 
and hypothyroidism affect the mRNA-level expression 
of apoptosis and cell cycle pathway-focused genes in 
gene-specific manner and that these changes to gene 
expression can be responsible for the apoptosis signs 
and symptoms associated with thyroid pathology.
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